List view / Grid view
Explore how FDA’s Project Optimus is reshaping oncology drug dosing strategies, with insights on precision medicine, adaptive trial designs, and the role of CROs in optimising patient outcomes.
Insilico Medicine’s AI-designed drug ISM5939 has received FDA IND clearance for treating solid tumours. By targeting ENPP1, it enhances anti-tumour immunity and is set to begin Phase I trials soon.
Researchers have identified over 3,000 harmful genetic changes that could disrupt normal RAD51C function.
Researchers have developed a prediction model to ascertain breast cancer survivors’ risk of persistent taxane-induced peripheral neuropathy.
A human pancreatic cancer fibrotic barrier model illuminates how targeting the TGFβ/ROCK2/YAP signalling axis could enhance drug delivery.
A specialised drug-loaded nanoparticle, which can cross the blood-brain barrier, shrunk both breast tumours and breast cancer cells.
The discovery that one missing copy of MUTYH could increase the risk of cancers may lead to therapeutics against solid tumours.
New findings will enable the development of safer PARP inhibitors that inhibit PARP’s enzymatic activity without trapping it on DNA.
Tumours with a greater IGR burden could respond better to immune checkpoint blockades, advancing precise treatments for patients.
Low-dose positron emission mammography (PEM) has a high sensitivity for detecting cancer and reduces the likelihood of false positives.
Researchers observed significant upregulation of Siglec-15 in the tumour microenvironment in bone tumour samples from breast cancer patients.
Inhibition of FAM3C expression in cancer-associated adipocytes during early tumour development holds promise as a novel treatment approach.
Researchers discover a key metabolic process that cancer cells use to grow in a nutrient deprived environment, which could be a new target.
New imaging technology called fluorescence lifetime (FLT) imaging improves the accuracy of cancer surgery for multiple tumour types.
Findings from using a 3D hydrogel to study how cancer cells physically tear the basement membrane offers promise for targeted treatment.
